Skip to content

Comparison of Rosuvastatin with Rosuvastatin plus zinc in improving serum lipid levels among dyslipidemia patients.

A comparative evaluation of safety and efficacy of Rosuvastatin with and without Zinc as an adjuvant in pharmacotherapy of dyslipidemia in tertiary care Hospital, Kanpur (U.P) - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/074541
Enrollment
410
Registered
2024-10-01
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E785- Hyperlipidemia, unspecified

Interventions

Intervention1: Rosuvastatin and Zinc: Rosuvastatin10 mg and Zinc 25 mg OD orally for 12 weeks Control Intervention1: Rosuvastatin: Rosuvastatin 10mg oral tablet OD for 12 weeks

Sponsors

Mahima Singh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients having serum LDL cholesterol above 130mg/dl, Serum triglycerides above or equal to 150mg/dl and less than or equal to 500mg/dl. Patients who are able to adequately maintain diary. Patients who are able and are willing to comply with the protocol and have signed IEC or IRB approved ICF

Exclusion criteria

Exclusion criteria: Fasting serum triglyceride (TG) level above 500 mg/dl, Medical history of systemic infection within 6 weeks of study initiation, Medical history of unstable angina, myocardial infarction, heart failure or stroke within 3 months of the study, Uncontrolled hypertension (systolic blood pressure above 160 mm Hg and/or diastolic blood pressure above 100 mm Hg), Uncontrolled diabetes mellitus (FBS above 300 mg/dl in patients with diabetes), ALT and AST greater than 2x upper limit of normal, Impaired renal function (creatinine greater than or equal to 2.0 mg/dl), Suffering from malabsorption syndrome or inflammatory bowel disease, Pregnancy/Lactation, Alcoholism, Patients on drugs that can increase the incidence of statin induced myopathy, Patient on chronic anti-inflammatory or antioxidant drugs within 6 weeks of study initiation

Design outcomes

Primary

MeasureTime frame
Efficacy in achieving target LDL-C and triglyceride levelsTimepoint: 6 and 12 weeks

Secondary

MeasureTime frame
To establish the patient characteristics based upon baseline data with dyslipidemia in Kanpur, UP population Incidence of any adverse drug reaction will be reported at Timepoints-every 2 week for12 weeks Changes Serum HDL-c levels at Timepoints-every 2 week for12 weeks Patient compliance Timepoint: Baseline, 6 and 12 weeks

Countries

India

Contacts

Public ContactMahima Singh

RAMA MEDICAL COLLEGE HOSPITAL AND RESEARCH CENTER

drnilamnigam@gmail.com09140190476

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026